Clinical Trials Logo

Filter by:
NCT ID: NCT02796274 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy (LHON)

Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)

Start date: May 2016
Phase:
Study type: Observational

The purpose of this survey is to collect visual acuity data from patients with LHON in order to establish the clinical course (natural history) and visual acuity outcomes in patients with a genetically confirmed diagnosis of LHON. In addition, this survey will generate data that will serve as comparator for the open-label study SNT-IV-006.

NCT ID: NCT02795767 Completed - Hemophilia A Clinical Trials

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

HAVEN 2
Start date: July 22, 2016
Phase: Phase 3
Study type: Interventional

This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.

NCT ID: NCT02795676 Completed - Fabry Disease Clinical Trials

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

BALANCE
Start date: June 2016
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients who had been treated for approximately 1 year with agalsidase beta and who had been on a stable dose of that product for at least 6 months were randomized in a 2:1 ratio to either switch to PRX-102 or to continue treatment with agalsidase beta. Both treatments were delivered by intravenous infusions every two weeks, at a dosage of 1 mg/kg.

NCT ID: NCT02795429 Completed - Clinical trials for Advanced Hepatocellular Carcinoma

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Start date: June 15, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered intravenously (i.v.) as a single agent or in combination with capmatinib administered orally in adult patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT02793726 Completed - Clinical trials for Prostheses and Implants

The Effects of Large Head MoM Hip Prosthesis on Soft Tissue: Study With 3 Tesla NMR

MoM_&_3Tesla
Start date: June 2016
Phase:
Study type: Observational

Symptomatic and asymptomatic patients wearing Metal on Metal hip prosthesis will be enrolled in the study and periimplant pseudotumors will be searched by means of NMR (Nuclear Magnetic Resonance).

NCT ID: NCT02793050 Completed - Clinical trials for Sarcoma, Soft Tissue

Retrospective Study of Trabectedin in Soft Tissue Sarcomas

TrObs
Start date: June 15, 2016
Phase:
Study type: Observational

This is an independent, observational, retrospective post marketing study on the use of trabectedin in a clinical setting. A data collection on the clinical use of the drug will help to improve knowledge and might contribute to optimize the clinical use of the drug.

NCT ID: NCT02792231 Completed - Clinical trials for Relapsing Multiple Scelrosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

ASCLEPIOS II
Start date: August 26, 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

NCT ID: NCT02792218 Completed - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

ASCLEPIOS I
Start date: September 20, 2016
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

NCT ID: NCT02791230 Completed - Clinical trials for Transthyretin (TTR) Amyloid Cardiomyopathy

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Start date: June 13, 2016
Phase: Phase 3
Study type: Interventional

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

NCT ID: NCT02790138 Completed - Pouchitis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis

EARNEST
Start date: October 12, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of vedolizumab intravenous (IV) and placebo in terms of the percentage of participants with chronic or recurrent pouchitis achieving clinically relevant remission.